Future research could focus on developing small-molecule drugs targeting taurine transporters or improving T cell function through taurine supplements, combined with spatial metabolomics to monitor dynamic microenvironmental changes in real time, thereby promoting a paradigm shift in bladder cancer therapy from single-target approaches to metabolism-immunity network regulation. The gene discussed is SLC6A6; the disease is urinary bladder cancer.